You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firms intend to seek CE marking and US Food and Drug Administration clearance for the test.
The company's microchip-based technology will detect viral and bacterial genetic material using both isothermal amplification and electrochemical measurements.
The test detects and differentiates respiratory syncytial virus and human metapneumovirus on the firm's Solana rapid molecular platform.
The assay runs on the Panther Fusion system, which combines transcription-mediated amplification, real-time TMA, and real-time PCR with full sample-to-result automation.
The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.
The assay was cleared and CLIA-waived for use on Quidel's Sofia 2 instrument for the detection of RSV using nasopharyngeal swab and nasopharyngeal aspirate/wash specimens.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The firm said that its test is the first on the market to detect RSV infection at the point of care in 13 minutes or less.
This is the first assay approved on the firm's next-generation platform-based immunoassay testing system, with assays for influenza and Strep A to follow.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.